UthPeak™ NMNH: 5 Years Younger Clinically Proven

Overview


Effepharm

NMNH, the reduced form of NMN, is a potent NAD+ precursor.

UthPeak™ reduced NMN (NMNH), the world’s first Self-GRAS approved, US patent-pending reduced NMN, completed the first, largest and longest Phase I clinical trial, demonstrating a remarkable 5-year age reversal validated by UCLA’s epigenetic study in “Aging” the global golden standard for measuring biological age.

Highlights of the clinical trial are:

● NAD+ Levels: Increased by 3 times

● Biological Age: Reduced by an average of 5 years

● Energy Levels: Enhanced by 35%

● Emotional Health: Improved by 31%

Contact us for more clinical study details.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

The Global Regulatory Advantage Behind UTHEVER® NMN

The Global Regulatory Advantage Behind UTHEVER® NMN

Paid for by Effepharm Ltd

White Paper

Regulatory uncertainty remains one of the biggest challenges for NMN brands. Choosing the wrong ingredient could lead to compliance risks & market restrictions.

Discover UTHEVER® NMN’s Global Regulatory Landscape

Discover UTHEVER® NMN’s Global Regulatory Landscape

Paid for by Effepharm Ltd

White Paper

NMN has long faced regulatory challenges. Today, that landscape is changing. We consistently invest in scientific research & quality development, aiming to establish UTHEVER® as the world’s most compliant NMN ingredient brand.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.